When you or someone you love receives a cancer diagnosis, the first question is always: Where should I go for the best possible outcome?
For many international patients, China has become a compelling answer — not because it is cheaper (though it often is), but because for certain cancer types, Chinese hospitals have accumulated a depth of clinical experience that is simply unmatched anywhere else in the world.
This article walks you through the specific cancers where China has developed world-leading expertise, the data behind those claims, and — just as importantly — the types of cancer where cross-border treatment may not be the right choice.
Why Certain Cancer Types? The Volume Advantage
China’s advantage in treating specific cancers is not accidental. It is driven by epidemiology:
| Cancer Type | Global Annual Cases | China Annual Cases | China’s Share |
|---|---|---|---|
| Lung cancer | 2.2 million | 850,000 | 39% |
| Liver cancer | 860,000 | 430,000 | 50% |
| Esophageal cancer | 600,000 | 320,000 | 53% |
| Gastric cancer | 1.1 million | 480,000 | 44% |
| Nasopharyngeal carcinoma | 130,000 | 60,000 | 46% |
Source: Globocan 2022 (WHO/IARC).
When a Chinese hospital treats 10,000 cases of a specific cancer per year while a US hospital treats 500, the Chinese team will inevitably develop deeper expertise. In medicine, volume directly correlates with outcomes. Hospitals that see more cases develop better protocols, faster diagnoses, more refined surgical techniques, and lower complication rates.
Cancer 1: Nasopharyngeal Carcinoma (NPC)
Why China Excels
NPC is rare in most of the world (incidence of <1 per 100,000 in the US and Europe) but endemic in southern China (incidence of 20-50 per 100,000 in Guangdong Province). This means Chinese oncologists — particularly in Guangzhou and Hong Kong — have experience that is orders of magnitude beyond their Western counterparts.
SYSU Cancer Center (Guangzhou) treats approximately 5,000 new NPC patients annually — more than most US hospitals treat in a decade.The center published the largest series of NPC treatment outcomes in the world, with over 10,000 patients included.### Treatment Approach
Standard treatment for NPC is radiation therapy (with or without chemotherapy) due to its location near critical head and neck structures. Chinese centers lead in:
Intensity-modulated radiation therapy (IMRT) — refined through decades of experienceInduction chemotherapy protocols developed in China are now used globallyImmunotherapy combinations — multiple Chinese trials have shown PD-1 inhibitors improve outcomes in advanced NPCRe-irradiation techniques for recurrent disease### Outcomes
| Metric | SYSU Cancer Center | US/European Centers |
|---|---|---|
| Stage I, 5-year survival | 95%+ | 90-95% |
| Stage II, 5-year survival | 85-90% | 80-85% |
| Stage III, 5-year survival | 75-80% | 65-75% |
| Stage IV, 5-year survival | 50-60% | 40-50% |
Source: Published data from SYSUCC and matched SEER (US) data. Note that differences reflect volume-driven expertise rather than different treatment approaches.
Best Hospitals for NPC in China
Sun Yat-sen University Cancer Center (Guangzhou) — #1 in China, global leaderCancer Hospital, Chinese Academy of Medical Sciences (Beijing)Fudan University Shanghai Cancer Center (Shanghai)## Cancer 2: Esophageal Cancer
Why China Excels
China accounts for over half of all esophageal cancer cases globally. The high incidence is driven by dietary factors (hot beverages, pickled foods), alcohol and tobacco use, and genetic susceptibility in certain populations. This volume has translated into unmatched surgical expertise.
Chinese thoracic surgeons have pioneered many of the techniques now used globally for esophageal cancer surgery.
Treatment Approach
Minimally invasive esophagectomy (MIE) — performed robotically or thoracoscopically/laparoscopically at high-volume centersNeoadjuvant chemoradiotherapy — protocols refined through Chinese clinical trialsImmunotherapy — PD-1 inhibitors now used as first-line treatment for advanced disease (toripalimab and camrelizumab both approved for esophageal cancer in China)Postoperative enhanced recovery — Chinese ERAS protocols cut hospital stays to 7-10 days### Outcomes
High-volume Chinese centers report:
5-year survival for stage II: 60-70%5-year survival for stage III: 35-50%Operative mortality at high-volume centers: <2%Anastomotic leak rate: 5-10% (comparable with international benchmarks)### Best Hospitals for Esophageal Cancer
Cancer Hospital, Chinese Academy of Medical Sciences (Beijing)Fudan University Shanghai Cancer Center (Shanghai) — #1 in China for esophageal surgerySYSU Cancer Center (Guangzhou) — strong esophageal programShanghai Chest Hospital — thoracic specialty center## Cancer 3: Liver Cancer (Hepatocellular Carcinoma)
Why China Excels
China accounts for half of all liver cancer cases globally, driven by high rates of hepatitis B virus (HBV) infection. HBV-related HCC is the dominant form in China, giving Chinese hepatobiliary surgeons and interventional radiologists immense experience.
Treatment Approach
Chinese centers offer a comprehensive range of liver cancer treatments:
Surgical resection — high-volume centers perform 500+ hepatic resections annuallyLiver transplantation — China performs the second-highest number of liver transplants globally (after the US)Radiofrequency/Microwave ablation — same technology, more experienceTransarterial chemoembolization (TACE) — developed and refined in AsiaTransarterial radioembolization (TARE) — available at major centersTargeted therapy — Sorafenib, Lenvatinib, and domestic TKI optionsImmunotherapy — Atezolizumab + Bevacizumab, Sintilimab + IBI305 (domestic), and ongoing clinical trialsHAIC (Hepatic Artery Infusion Chemotherapy) — Chinese centers have high-volume experience with this technique### Domestic Drug Advantage
| Drug | US Price (per month) | China Price (per month) |
|---|---|---|
| Lenvatinib (Lenvima) | $15,000-20,000 | $3,000-5,000 (imported) |
| Sorafenib (Nexavar) | $12,000-18,000 | $1,500-3,000 (domestic generic) |
| Atezolizumab + Bevacizumab | $20,000-30,000 | $6,000-12,000 (imported) |
| Sintilimab + IBI305 | N/A (China domestic) | $3,000-6,000 |
Best Hospitals for Liver Cancer
Eastern Hepatobiliary Surgery Hospital (Shanghai) — #1 in China for liver cancerNanfang Hospital (Guangzhou) — strong hepatobiliary programCancer Hospital, CAMS (Beijing)SYSU Cancer Center (Guangzhou)## Cancer 4: Gastric Cancer
Why China Excels
China has the highest number of gastric cancer cases of any country, driven partly by H. pylori infection, dietary habits (pickled foods, high salt), and genetic factors. Chinese surgeons perform an extraordinary volume of gastrectomies, and Chinese medical oncologists manage large numbers of advanced cases.
Treatment Approach
Robotic gastrectomy — Chinese centers have some of the largest robotic gastrectomy series in the worldD2 lymphadenectomy — standard practice in China (in contrast to the US where D2 is less common), leading to better staging and outcomesHIPEC — used for peritoneal metastases; Chinese centers have extensive experienceImmunotherapy — PD-1 inhibitors approved for advanced gastric cancer in China (nivolumab, pembrolizumab, sintilimab)Targeted therapy — trastuzumab for HER2+, ramucirumab for second-line, Claudin18.2 targeted therapies (especially strong in Chinese research now)### Outcomes
Chinese high-volume centers report:
5-year survival for stage II: 70-80% (D2 dissection)5-year survival for stage III: 30-50%R0 resection rate at high-volume centers: 95%+Morbidity: Comparable with Japanese and Korean benchmarks### Best Hospitals for Gastric Cancer
Cancer Hospital, CAMS (Beijing)Fudan University Shanghai Cancer Center (Shanghai)Peking University Cancer Hospital (Beijing)SYSU Cancer Center (Guangzhou)## Cancer 5: Lung Cancer
Why China Excels
Simple volume: China has 850,000 new lung cancer cases annually — more than any other country. Chinese thoracic surgeons perform more lobectomies, pneumonectomies, and segmentectomies than lung cancer surgeons anywhere else.
Treatment Approach
VATS lobectomy — standard approach at high-volume centers, accounting for 70-80% of lung cancer surgeriesRobotic-assisted thoracic surgery — growing rapidlyStereotactic body radiation therapy (SBRT) — for early-stage medically inoperable patientsTargeted therapy — all major driver mutations covered (EGFR, ALK, ROS1, BRAF, MET, NTRK, RET, KRAS G12C)Immunotherapy — extensive range of domestic PD-1 options### Access to Targeted Therapies
China’s drug approval system has accelerated access to novel targeted therapies. The following are available in China:
| Drug | Target | Available in China? | US Availability |
|---|---|---|---|
| Osimertinib (Tagrisso) | EGFR | Yes (imported + domestic generic) | Yes |
| Alectinib (Alecensa) | ALK | Yes (imported) | Yes |
| Lorlatinib (Lorbrena) | ALK/ROS1 | Yes (through Lecheng) | Yes |
| Selpercatinib (Retevmo) | RET | Yes (imported) | Yes |
| Sotorasib (Lumakras) | KRAS G12C | Yes (imported) | Yes |
| Ivonescimab | PD-1/VEGF | Yes (China domestic) | No (not available outside China) |
Best Hospitals for Lung Cancer
Cancer Hospital, CAMS (Beijing)Fudan University Shanghai Cancer Center (Shanghai)Shanghai Chest Hospital — thoracic specialty centerGZMU First Hospital (Guangzhou) — #1 nationally for respiratory medicineSYSU Cancer Center (Guangzhou)## Other Cancers Where China Has Strong Expertise
Colorectal Cancer
China has rising incidence of colorectal cancer and strong surgical outcomes. Robotic colorectal surgery is widely performed. Domestic PD-1 options for MSI-H tumors.
Breast Cancer
Breast cancer incidence is rising in China, and Chinese centers now have comparable outcomes to Western centers. Domestic trastuzumab biosimilar reduces costs by 90%. Chinese centers participate in global clinical trials for novel breast cancer therapies.
Pancreatic Cancer
Challenging in any setting, but Chinese centers at Shandong, Shanghai, and Beijing have developing expertise in borderline resectable and locally advanced pancreatic cancer.
Leukemia and Lymphoma – Hematological Malignancies
China has strong hematology departments at centers like Nanfang Hospital, Ruijin Hospital, and the Institute of Hematology. CAR-T therapy is widely available. Bone marrow transplant programs are mature.
Cancers Where China May Not Be the Best Choice
It is important to be honest: China is not the best option for every cancer type.
| Cancer Type | Reason | Better Destinations |
|---|---|---|
| Testicular cancer | Excellent outcomes in the West for standard regimens; China’s advantage is minimal | US, UK, Germany |
| Melanoma | Lower incidence in China; Western centers have more experience with immunotherapy combinations | US, Australia, Germany |
| Pediatric leukemia (standard risk) | Well-established protocols in the West; travel adds unnecessary complexity | Home country if quality care is available |
| Rare sarcomas | Better managed at specialized sarcoma centers in the US or Europe with multidisciplinary expertise | US, UK, Germany, Italy |
| Gynecological cancers (ovarian, endometrial) | Strong outcomes in both East and West; choose based on cost/timeline | Comparable globally |
The myMedVia Assessment Process
For every patient, myMedVia conducts a structured assessment to determine whether China is the right choice for your specific cancer:
Cancer type and stage: Is this a cancer where China has demonstrated excellence?Treatment history: Have you had prior treatment that needs to be considered?Genomic profile: Are there China-specific drug options that would benefit you?Timeline: Can you wait for travel, or do you need immediate treatment?Personal considerations: Willingness to travel, budget, support systemBased on this assessment, we recommend either:
Proceed to China with specific hospital and specialist recommendationsConsider other destinations if a different center is better matchedStay in your home system if timely, high-quality care is available locally## Conclusion: Matching the Cancer to the Center
China’s strength in cancer care is not uniform — it is concentrated in specific cancer types where high local incidence has created world-leading expertise. For patients with nasopharyngeal carcinoma, esophageal cancer, liver cancer, gastric cancer, or lung cancer, Chinese hospitals offer outcomes that match or exceed anything available in the West at a fraction of the cost.
For other cancer types, the decision depends on your specific situation — cost, timeline, treatment options, and personal preferences.
The key is honest, data-driven matching of your diagnosis to the right center. That is exactly what myMedVia provides.
Not sure which hospital or doctor is right for your condition? Let us match you to the best option from our partner hospital network based on your specific needs. Free evaluation →
Fast · Affordable · Certain
